Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Uric acid and hypertension.

Michael Schachter1

  • 1Department of Clinical Pharmacology, National Heart and Lung Institute, Imperial College School of Medicine, St Mary's Hospital, London, UK. M.Schachter@imperial.ac.uk

Current Pharmaceutical Design
|December 27, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health information technology tools to accelerate gastrointestinal evaluation in patients with iron deficiency anaemia: a cluster randomised controlled trial.

BMJ open quality·2024
Same author

Seamless Integration of Computer-Adaptive Patient Reported Outcomes into an Electronic Health Record.

Applied clinical informatics·2023
Same author

Double-Positive Anti-Glomerular Basement Membrane Antibody and Myeloperoxidase Antineutrophil Cytoplasmic Autoantibody-Associated Glomerulonephritis Post COVID-19 mRNA vaccine: A Case Series of 4 Patients.

Canadian journal of kidney health and disease·2023
Same author

Outreach to Promote Management of Cardiovascular Risk in Primary Care Among Patients With Rheumatoid Arthritis Seen in Rheumatology Practice.

ACR open rheumatology·2020
Same author

Commentary.

Journal of the renin-angiotensin-aldosterone system : JRAAS·2015
Same author

Novel oral anticoagulants: too good to be true?

Postgraduate medical journal·2014
Same journal

Precision Nanotechnology in Oral Oncology: From Biomarker-Guided Targeting to AI-Driven Theranostics.

Current pharmaceutical design·2026
Same journal

Pharmacological Insights into Medicinal Plants and Phytomolecules for the Management of Alopecia with Mechanistic Perspectives and Therapeutic Potential.

Current pharmaceutical design·2026
Same journal

Addressing Challenges, Regulatory Shifts, and the Need for Cost-Effective Alternatives for Complex Topical Formulations.

Current pharmaceutical design·2026
Same journal

The Mechanism of Huaiqihuang in the Treatment of Nephrotic Syndrome: An Integrated Study Based on Network Pharmacology, Molecular Docking, Molecular Dynamics Simulation, and Experimental Validation.

Current pharmaceutical design·2026
Same journal

Resveratrol and the NLRP3 Inflammasome: Unlocking the Anti-inflammatory Potential of a Natural Compound.

Current pharmaceutical design·2026
Same journal

The Use of Hemostatic Agents in Traumatic Bleeding: One Size Does Not Fit All.

Current pharmaceutical design·2026
See all related articles

High uric acid levels link to cardiovascular disease and metabolic syndrome, potentially predicting outcomes. Further research is needed to confirm if lowering uric acid benefits hypertension management.

Area of Science:

  • Biochemistry
  • Cardiovascular Medicine
  • Nephrology

Background:

  • Elevated uric acid is linked to cardiovascular disease and metabolic syndrome.
  • Hyperuricemia may predict clinical outcomes and hypertension onset.
  • Uric acid's role as an independent risk factor requires further clarification due to its association with other factors.

Purpose of the Study:

  • To explore the association between uric acid levels and cardiovascular disease and metabolic syndrome.
  • To investigate the potential role of uric acid in the pathogenesis of hypertension.
  • To examine the therapeutic implications of targeting uric acid in cardiovascular and hypertensive conditions.

Main Methods:

  • Review of existing literature on uric acid, cardiovascular disease, metabolic syndrome, and hypertension.

Related Experiment Videos

  • Analysis of pathophysiological mechanisms linking uric acid to renal and vascular damage.
  • Exploration of data regarding the impact of lowering uric acid on blood pressure.

    • Main Results:

    • Increased uric acid is associated with cardiovascular disease, metabolic syndrome, and hypertension.
    • Uric acid may contribute to renal and vascular damage, including endothelial dysfunction.
    • Limited evidence suggests lowering uric acid might reduce blood pressure in some cases.

    Conclusions:

    • The precise role of uric acid as an independent risk factor for cardiovascular disease and hypertension remains under investigation.
    • The relationship between elevated uric acid and triglyceride levels in metabolic syndrome needs further definition.
    • Further research is required to determine if uric acid should be a therapeutic target and to establish optimal methods for lowering serum urate levels.